MedTrace Logo

Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer

NCT03431415 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2021-08-24

No results posted yet for this study

Summary

The primary objective of this study is disease free survival rate at 5 years in stage IA2 (T1aN0M0 or T1bN0M0 only) non-small cell lung cancer (NSCLC) patients treated either by surgery or stereotactic body radiation therapy (SBRT).

Conditions

  • Non-small Cell Lung Cancer Stage I
  • Surgery
  • Stereotactic Body Radiation Therapy

Interventions

PROCEDURE

Anatomical Segmentectomy, Lobectomy or Bilobectomy

Lung Cancer Anatomical Resection

RADIATION

Stereotactic Body Radiation Therapy

SBRT treatment. 48Gy in 4 sessions for peripheral lesions and 50Gy in 5 sessions for central lesions.

Sponsors & Collaborators

  • CHU de Quebec-Universite Laval

    collaborator OTHER

  • Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec

    lead OTHER

Principal Investigators

  • Paula A Ugalde Figueroa, MD · Associate Professor, Thoracic Surgeon, Research Coordinator

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-28
Primary Completion
2020-03-31
Completion
2025-02-28

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03431415 on ClinicalTrials.gov